`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________________________________
`
`
`HOPEWELL PHARMA VENTURES, INC.,
`Petitioner,
`
`v.
`
`MERCK SERONO SA,
`Patent Owner.
`
`____________________________________________
`
`Case IPR2023-00481
`U.S. Patent No. 8,377,903
`____________________________________________
`
`PATENT OWNER’S UPDATE TO MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`Patent Owner’s Update to Mandatory Notices
`IPR2023-00481
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner respectfully submits the
`
`
`
`following updated related matters for its Mandatory Notices.
`
`I.
`
`37 C.F.R. § 42.8(b)(2) – Related Matters
`
`U.S. Patent No. 8,377,903 (“the ’903 patent”) is a patent-in-suit in the
`
`following litigations: Merck KGaA, Merck Serono SA, and Ares Trading SA v.
`
`Accord Healthcare, Inc., No. 1:22-cv-00974-GBW (D. Del.), Merck KGaA, Merck
`
`Serono SA, and Ares Trading SA v. Hopewell Pharma Ventures, Inc., No. 1:22-cv-
`
`01365-GBW (D. Del.), and Merck KGaA, Merck Serono SA, and Ares Trading SA
`
`v. Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited, No. 1:23-cv-
`
`00039-GBW (D. Del.).
`
`The ’903 patent is related to U.S. Patent No. 7,713,947 (“the ’947 patent”),
`
`where the ’903 patent issued from an application that was filed as a continuation of
`
`the ’947 patent. Petitioner concurrently filed a petition for inter partes review of
`
`the ’947 patent, which was filed as proceeding no. IPR2023-00480. Additionally,
`
`the ’947 and the ’903 patents are subject to the following inter partes review
`
`petitions: TWi Pharmaceuticals, Inc. v. Merck Serono SA, IPR2023-00049 and TWi
`
`Pharmaceuticals, Inc. v. Merck Serono SA, IPR2023-00050, respectively.
`
`On February 10, 2023, Petitioner filed a petition for inter partes review of
`
`U.S. Patent No. 10,849,919 (“the ’919 patent”), which was filed as proceeding no.
`
`
`
`1
`
`
`
`IPR2023-00482. The ’919 patent is assigned to Ares Trading SA and is a patent-
`
`Patent Owner’s Update to Mandatory Notices
`IPR2023-00481
`
`
`in-suit in the judicial matters identified above.
`
`Date: March 1, 2023
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Emily R. Whelan/
`Emily R. Whelan (Reg. No. 50,391)
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`Tel: (617) 526-6567
`Email: Emily.Whelan@wilmerhale.com
`
`2
`
`
`
`
`
`Patent Owner’s Update to Mandatory Notices
`IPR2023-00481
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on March 1, 2023, I caused a true and correct copy of
`
`the foregoing Patent Owner’s Update to Mandatory Notices Under 37 C.F.R. §
`
`42.8 to be served via e-mail, as consented to by Petitioner, on the following
`
`attorneys of record:
`
`eellison-PTAB@sternekessler.com
`opartington-PTAB@sternekessler.com
`cvira-PTAB@sternekessler.com
`jcrozendaal-PTAB@sternekessler.com
`PTAB@sternekessler.com
`
`
`
`
`By: /Cindy Kan/
`Cindy Kan (Reg. No. 76,385)
`Wilmer Cutler Pickering Hale and Dorr LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`Tel: 212-295-6470
`Email: Cindy.Kan@wilmerhale.com
`
`
`
`3
`
`